metopimazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1784	14008-44-7

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

metopimazine hydrochloride
metopimazine HCl
metopimazine
vogalene

Molecular weight: 445.60
Formula: C22H27N3O3S2
CLOGP: 1.30
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 83.71
ALOGS: -4.37
ROTB: 6

Drug dosage:

Dose	Unit	Route
15	mg	O
15	mg	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	12.14 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4 hours	Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	73.30	41.15	50	1007	228008	50376059
Cholestasis	60.70	41.15	22	1035	25379	50578688
Febrile bone marrow aplasia	51.54	41.15	14	1043	6297	50597770
Hyperkalaemia	44.04	41.15	21	1036	48068	50555999
Poisoning deliberate	43.99	41.15	13	1044	7899	50596168

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Analgesic drug level increased	57.09	53.02	10	605	582	29573330

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	101.72	34.74	89	1664	449151	64047828
Cholestasis	61.17	34.74	28	1725	44844	64452135
Poisoning deliberate	60.51	34.74	20	1733	13438	64483541
Coma	59.07	34.74	34	1719	87581	64409398
Hepatitis	45.56	34.74	23	1730	45559	64451420
Febrile bone marrow aplasia	43.76	34.74	15	1738	11240	64485739
Analgesic drug level increased	40.97	34.74	10	1743	2260	64494719
Hepatocellular injury	37.11	34.74	20	1733	45215	64451764
Pancreatitis acute	35.30	34.74	19	1734	42836	64454143

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A04AD05	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.41	acidic
pKa2	8.95	Basic
pKa3	3.45	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	10.15		CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	9.21		CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.08		CHEMBL

External reference:

ID	Source
D05010	KEGG_DRUG
C0066469	UMLSCUI
CHEBI:135726	CHEBI
CHEMBL398615	ChEMBL_ID
DB13591	DRUGBANK_ID
C005260	MESH_SUPPLEMENTAL_RECORD_UI
11140	IUPHAR_LIGAND_ID
2178	INN_ID
238S75V9AV	UNII
26388	PUBCHEM_CID
29954	RXNORM
005826	NDDF

Pharmaceutical products:

None